{
    "@xmlns:dc": "http://purl.org/dc/elements/1.1/",
    "dc:title": "Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication : a study with risperidone lonn-acting injection",
    "dc:creator": [
        "EMSLEY, Robin",
        "OOSTHUIZEN, Petrus",
        "KOEN, Liezl",
        "NIEHAUS, Dana J. H",
        "MEDORI, Rossella",
        "RABINOWITZ, Jonathan"
    ],
    "dc:relation": "International clinical psychopharmacology -- Int. clin. psychopharmacol, ISSN 0268-1315, Vol. 23 (6) , pp. 325-331",
    "dc:date": "2008",
    "dc:type": [
        "Text",
        "Article"
    ],
    "dc:language": "English",
    "dc:publisher": "Lippincott Williams & Wilkins",
    "dc:format": [
        "print",
        "7 p. ; 3/4 p"
    ],
    "dc:subject": [
        {
            "@xml:lang": "fr",
            "#text": "Antagoniste dopamine"
        },
        {
            "@xml:lang": "fr",
            "#text": "Antagoniste sérotonine"
        },
        {
            "@xml:lang": "fr",
            "#text": "Benzisoxazole dérivé"
        },
        {
            "@xml:lang": "fr",
            "#text": "Forme pharmaceutique"
        },
        {
            "@xml:lang": "fr",
            "#text": "Psychose"
        },
        {
            "@xml:lang": "fr",
            "#text": "Récepteur dopaminergique D2"
        },
        {
            "@xml:lang": "fr",
            "#text": "Récepteur sérotoninergique"
        },
        {
            "@xml:lang": "fr",
            "#text": "Traitement"
        },
        {
            "@xml:lang": "fr",
            "#text": "Antipsychotique atypique"
        },
        {
            "@xml:lang": "fr",
            "#text": "Forme libération contrôlée"
        },
        {
            "@xml:lang": "fr",
            "#text": "Homme"
        },
        {
            "@xml:lang": "fr",
            "#text": "Médicament"
        },
        {
            "@xml:lang": "fr",
            "#text": "Neuroleptique"
        },
        {
            "@xml:lang": "fr",
            "#text": "Pharmacothérapie"
        },
        {
            "@xml:lang": "fr",
            "#text": "Premier épisode"
        },
        {
            "@xml:lang": "fr",
            "#text": "Psychotrope"
        },
        {
            "@xml:lang": "fr",
            "#text": "Rispéridone"
        },
        {
            "@xml:lang": "fr",
            "#text": "Rémission"
        },
        {
            "@xml:lang": "fr",
            "#text": "Schizophrénie"
        },
        {
            "@xml:lang": "en",
            "#text": "Dopamine antagonist"
        },
        {
            "@xml:lang": "en",
            "#text": "Serotonin antagonist"
        },
        {
            "@xml:lang": "en",
            "#text": "Benzisoxazole derivatives"
        },
        {
            "@xml:lang": "en",
            "#text": "Dosage form"
        },
        {
            "@xml:lang": "en",
            "#text": "Psychosis"
        },
        {
            "@xml:lang": "en",
            "#text": "D2 Dopamine receptor"
        },
        {
            "@xml:lang": "en",
            "#text": "Serotonine receptor"
        },
        {
            "@xml:lang": "en",
            "#text": "Treatment"
        },
        {
            "@xml:lang": "en",
            "#text": "Atypical antipsychotic"
        },
        {
            "@xml:lang": "en",
            "#text": "Controlled release form"
        },
        {
            "@xml:lang": "en",
            "#text": "Human"
        },
        {
            "@xml:lang": "en",
            "#text": "Drug"
        },
        {
            "@xml:lang": "en",
            "#text": "Neuroleptic"
        },
        {
            "@xml:lang": "en",
            "#text": "Pharmacotherapy"
        },
        {
            "@xml:lang": "en",
            "#text": "First episode"
        },
        {
            "@xml:lang": "en",
            "#text": "Psychotropic"
        },
        {
            "@xml:lang": "en",
            "#text": "Risperidone"
        },
        {
            "@xml:lang": "en",
            "#text": "Remission"
        },
        {
            "@xml:lang": "en",
            "#text": "Schizophrenia"
        },
        {
            "@xml:lang": "en",
            "#text": "long-acting injectable"
        },
        {
            "@xml:lang": "en",
            "#text": "remission"
        },
        {
            "@xml:lang": "en",
            "#text": "risperidone"
        },
        {
            "@xml:lang": "en",
            "#text": "schizophrenia"
        },
        {
            "@xml:lang": "es",
            "#text": "Antagonista dopamina"
        },
        {
            "@xml:lang": "es",
            "#text": "Antagonista serotonina"
        },
        {
            "@xml:lang": "es",
            "#text": "Benzisoxazol derivado"
        },
        {
            "@xml:lang": "es",
            "#text": "Forma farmacéutica"
        },
        {
            "@xml:lang": "es",
            "#text": "Psicosis"
        },
        {
            "@xml:lang": "es",
            "#text": "Receptor dopaminérgico D2"
        },
        {
            "@xml:lang": "es",
            "#text": "Receptor serotoninérgico"
        },
        {
            "@xml:lang": "es",
            "#text": "Tratamiento"
        },
        {
            "@xml:lang": "es",
            "#text": "Antipsicótico atípico"
        },
        {
            "@xml:lang": "es",
            "#text": "Forma liberación controlada"
        },
        {
            "@xml:lang": "es",
            "#text": "Hombre"
        },
        {
            "@xml:lang": "es",
            "#text": "Medicamento"
        },
        {
            "@xml:lang": "es",
            "#text": "Neuroléptico"
        },
        {
            "@xml:lang": "es",
            "#text": "Farmacoterapia"
        },
        {
            "@xml:lang": "es",
            "#text": "Primer episodio"
        },
        {
            "@xml:lang": "es",
            "#text": "Psicotropo"
        },
        {
            "@xml:lang": "es",
            "#text": "Risperidona"
        },
        {
            "@xml:lang": "es",
            "#text": "Remisión"
        },
        {
            "@xml:lang": "es",
            "#text": "Esquizofrenia"
        },
        "002B02B03: Psycholeptiques: tranquillisant, neuroleptique. / Psycholeptics: tranquillizer, neuroleptic.",
        "002B18C06A: Schizophrénie / Schizophrenia",
        "770-D: PSYCHOPATHOLOGIE. PSYCHIATRIE / Psychopathology. Psychiatry",
        "770-D03F01: Schizophrénie / Schizophrenia",
        "770-E: Psychopharmacologie / Psychopharmacology",
        "770-E03: Psycholeptiques: tranquillisant, neuroleptique… / Psycholeptics: tranquillizer, neuroleptic…"
    ],
    "dc:rights": [
        "Inist-CNRS",
        "Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS"
    ],
    "dc:identifier": "Inist-CNRS record number 20780505"
}